SAN DIEGO (Reuters) – New data on weight loss drugs that could compete with Novo Nordisk’s Wegovy are raising expectations there will soon be more options, and possibly lower prices, in an estimated $100 billion marketplace, doctors and pharmaceutical executives say. Drugmakers are ratcheting up their research and aiming for…Read More
AnalysisWeight loss drug candidates multiply spurring hopes of better outcomes lower costs
